Research programme: CD200-based therapeutics - Trillium Therapeutics

Drug Profile

Research programme: CD200-based therapeutics - Trillium Therapeutics

Alternative Names: Anti-CD 200 monoclonal antibodies; CD200 fusion protein; CD200Fc; TTI 200.7

Latest Information Update: 04 Jun 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Trillium Therapeutics
  • Class Monoclonal antibodies; Proteins
  • Mechanism of Action CD200 antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • Discontinued Immunological disorders; Transplant rejection

Most Recent Events

  • 02 Jun 2014 Stem Therapeutics changes its name to Trillium Therapeutics
  • 11 Apr 2013 Trillium Therapeutics has merged with Stem Cell Therapeutics Corp.
  • 12 Feb 2013 Discontinued - Preclinical for Immunological disorders in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top